Downregulation of immunosuppressive environment in patients with chronic HBV hepatitis on maintained remission

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Chaudhary, Belal ^a,b,c   Elkord, Eyad ^a,b,d  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF SALFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chronic HBV; Downregulation; Foxp3; Immunosuppressive; PD1PD L1

Indexed keywords

CD8 ANTIGEN; CYTOKINE; FAS LIGAND; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CELL DESTRUCTION; CHRONIC INFLAMMATION; DOWN REGULATION; GENE EXPRESSION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; NONHUMAN; NOTE; REGULATORY T LYMPHOCYTE; REMISSION; UPREGULATION; VIRUS INFECTION;

EID: 84926619178     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00052     Document Type: Note

References (24)

1. Germanidis G, Argentou N, Hytiroglou P, Vassiliadis T, Patsiaoura K, Germenis AE, et al. Liver FOXP3 and PD1/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation. Front Immunol (2013) 4:207. doi:10.3389/fimmu.2013.00207
2. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol (2006) 87:1439-49. doi:10.1099/vir.0.81920-0
3. Fletcher SP, Delaney WE. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis (2013) 33:130-7. doi:10.1055/s-0033-1345713
4. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 49:S72-84. doi:10.1002/hep.22884
5. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther (2010) 15:133-43. doi:10.3851/IMP1497
6. El-Badawy O, Sayed D, Badary MS, Abd-Alrahman ME, El-Feky MA, Thabit AG. Relations of regulatory T cells with hepatitis markers in chronic hepatitis B virus infection. Hum Immunol (2012) 73:335-41. doi:10.1016/j.humimm.2012.01.014
7. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis (2007) 7:804-13. doi:10.1016/S1473-3099(07)70289-X
8. Wang L, Qiu J, Yu L, Hu X, Zhao P, Jiang Y. Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med (2014) 12:251. doi:10.1186/s12967-014-0251-9
9. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 82:5043-53. doi:10.1128/JVI.01548-07
10. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol (2008) 82:21-30. doi:10.1128/JVI.01768-07
11. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 177:739-47. doi:10.4049/jimmunol.177.1.739
12. Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat (2010) 17(Suppl 1):34-43. doi:10.1111/j.1365-2893.2010.01269.x
13. Speletas M, Argentou N, Germanidis G, Vassiliadis T, Mantzoukis K, Patsiaoura K, et al. Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm (2011) 2011:827565. doi:10.1155/2011/827565
14. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut (2005) 54:1024-33. doi:10.1136/gut.2004.053850
15. Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther (2014) 14:931-45. doi:10.1517/14712598.2014.900539
16. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 236:219-42. doi:10.1111/j.1600-065X.2010.00923.x
17. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology (2009) 50:1625-37. doi:10.1002/hep.23173
18. Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat (2010) 17:453-8. doi:10.1111/j.1365-2893.2010.01313.x
19. Lehtimaki S, Lahesmaa R. Regulatory T cells control immune responses through their non-redundant tissue specific features. Front Immunol (2013) 4:294. doi:10.3389/fimmu.2013.00294
20. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity (2009) 30:626-35. doi:10.1016/j.immuni.2009.05.002
21. Li F, Tian Z. The liver works as a school to educate regulatory immune cells. Cell Mol Immunol (2013) 10:292-302. doi:10.1038/cmi.2013.7
22. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2010) 138:682-93. doi:10.1053/j.gastro.2009.09.052
23. Oo YH, Sakaguchi S. Regulatory T-cell directed therapies in liver diseases. J Hepatol (2013) 59:1127-34. doi:10.1016/j.jhep.2013.05.034
24. Wang L, Zou ZQ, Liu CX, Liu XZ. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. J Immunol Methods (2014) 407:1-8. doi:10.1016/j.jim.2014.04.004